Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing
Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013
Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant
Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo
J&J insulin pumps are at risk of hacking; Merrimack CEO leaves and cuts workforce; Japanese scientists wins Nobel
Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.
Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.
The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media